Page last updated: 2024-08-26

diosgenin and daunorubicin

diosgenin has been researched along with daunorubicin in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Strassburg, CP; Tukey, RH1
Bayet, C; Darbour, N; Di Pietro, A; Dijoux-Franca, MG; Doreau, A; Dumontet, C; Guilet, D; Nguyen, VT; Phung, BH; Raad, I1
Fan, L; Fu, M; Li, G; Li, J; Li, X; Liu, J; Pan, W; Wang, X; Wang, Y; Yang, Y; Yu, Y1
Cai, FY; Fu, M; He, SY; Jing, M; Ju, RJ; Kong, L; Li, XT; Liu, JJ; Liu, XZ; Niu, FJ; Yao, XM; Zhang, L1

Reviews

1 review(s) available for diosgenin and daunorubicin

ArticleYear
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
    Annual review of pharmacology and toxicology, 2000, Volume: 40

    Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic

2000

Other Studies

3 other study(ies) available for diosgenin and daunorubicin

ArticleYear
Selective modulation of P-glycoprotein activity by steroidal saponines from Paris polyphylla.
    Fitoterapia, 2009, Volume: 80, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cyclosporine; Daunorubicin; Diosgenin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Ecdysteroids; Ecdysterone; Humans; Immunosuppressive Agents; K562 Cells; Leukemia; Magnoliopsida; Membrane Transport Modulators; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Plant Extracts; Rhizome; Saponins; Spirostans; Steroids

2009
Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer.
    International journal of nanomedicine, 2019, Volume: 14

    Topics: A549 Cells; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Daunorubicin; Diosgenin; Drug Delivery Systems; Female; Humans; Liposomes; Lung Neoplasms; Matrix Metalloproteinase 2; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Oligopeptides; Particle Size; Static Electricity; Wound Healing

2019
GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial-mesenchymal transition.
    Drug development and industrial pharmacy, 2020, Volume: 46, Issue:6

    Topics: Breast Neoplasms; Cell Line, Tumor; Daunorubicin; Diosgenin; Epithelial-Mesenchymal Transition; Humans; Liposomes

2020